| Literature DB >> 29783955 |
Saiful Safuan Md-Sani1, Julina Md-Noor2, Winn-Hui Han1, Syang-Pyang Gan1, Nor-Salina Rani1, Hui-Loo Tan1, Kanimoli Rathakrishnan1, Mohd Azizuddin A-Shariffuddin3, Marzilawati Abd-Rahman1.
Abstract
BACKGROUND: Increasing incidence of dengue cases in Malaysia over the last few years has been paralleled by increased deaths. Mortality prediction models will therefore be useful in clinical management. The aim of this study is to identify factors at diagnosis of severe dengue that predicts mortality and assess predictive models based on these identified factors.Entities:
Keywords: Mortality; Predict; Severe dengue
Mesh:
Substances:
Year: 2018 PMID: 29783955 PMCID: PMC5963083 DOI: 10.1186/s12879-018-3141-6
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Clinical characteristics and laboratory parameters of 199 patients hospitalised with severe dengue in 2014
| All ( | Died ( | Survived ( | |||||
|---|---|---|---|---|---|---|---|
|
| n(%) or median(IQR) |
| n(%) or median(IQR) |
| n(%) or median(IQR) | ||
| Age, years | 197 | 30.8 (24.7–41.3) | 20 | 43.5 (30.3–54.8) | 177 | 30.2 (23.9–38.9) | 0.0003 |
| BMI | 117 | 24.9 (21.3–29.7) | 6 | 23.6 (22.7–24.1) | 111 | 25.3 (21.3–30.0) | 0.29 |
| Gender, Male | 199 | 127 (63.8%) | 20 | 13 (65%) | 179 | 114 (63.7%) | 0.91 |
| Presence of any co-morbidity | 198 | 62 (31.2%) | 20 | 9 (45%) | 178 | 53 (29.6%) | 0.16 |
| Co-morbidity | |||||||
| COPD/BA | 9 (4.6%) | 0 (0%) | 9 (5.1%) | ||||
| DM | 24 (12.1%) | 5 (25%) | 19 (10.7%) | ||||
| Hypertension | 9 (4.6%) | 2 (10%) | 7 (3.9%) | ||||
| IHD | 2 (1%) | 1 (5%) | 1 (0.6%) | ||||
| Pregnancy | 8 (4%) | 1 (5%) | 7 (3.9%) | ||||
| Others | 10 (5.1%) | 0 (0%) | 10 (5.6%) | ||||
| Multiple co-morbidities | 198 | 20 (10.1%) | 20 | 5 (25%) | 178 | 15 (8.4%) | 0.04a |
| NS1 | 198 | 132 (66.7%) | 20 | 13 (65%) | 178 | 119 (66.9%) | 0.87 |
| High-titre IgG | 198 | 47 (23.7%) | 20 | 5 (25%) | 178 | 42 (23.6%) | 0.89 |
| IgM | 198 | 115 (58.1%) | 20 | 14 (70%) | 178 | 101 (56.7%) | 0.25 |
| Persistent vomiting | 198 | 114 (57.6%) | 20 | 14 (70%) | 178 | 100 (56.2%) | 0.24 |
| Abdominal pain | 198 | 89 (45%) | 20 | 7 (35%) | 178 | 82 (46.1%) | 0.35 |
| Lethargy | 198 | 96 (48.5%) | 20 | 15 (75%) | 178 | 81 (45.5%) | 0.01 |
| Palpable liver | 198 | 16 (8.1%) | 20 | 2 (10%) | 178 | 14 (7.9%) | 0.67a |
| Fluid accumulation | 198 | 44 (22.2%) | 20 | 4 (20%) | 178 | 40 (22.5%) | 1.00a |
| Bleed | 198 | 49 (24.8%) | 20 | 13 (65%) | 178 | 36 (20.2%) | < 0.0001a |
| Hct > 46 | 198 | 77 (38.9%) | 20 | 10 (50%) | 178 | 67 (37.6%) | 0.28 |
| Low Plt < 46 | 198 | 106 (53.5%) | 20 | 15 (75%) | 178 | 91 (51.1%) | 0.04 |
| Albumin < 34 | 198 | 106 (53.5%) | 20 | 13 (65%) | 178 | 93 (52.3%) | 0.28 |
| Number of warning signs | 199 | 20 | 179 | NSb | |||
| 0 | 9 (4.5%) | 0 (0%) | 9 (5.03%) | ||||
| 1 | 17 (8.5%) | 0 (0%) | 17 (9.5%) | ||||
| 2 | 35 (17.6%) | 2 (10%) | 33 (18.4%) | ||||
| 3 | 35 (17.6%) | 4 (20%) | 31 (17.3%) | ||||
| 4 | 49 (24.6%) | 6 (30%) | 43 (24.0%) | ||||
| 5 | 29 (14.6%) | 2 (10%) | 27 (15.1%) | ||||
| 6 | 16 (8%) | 3 (15%) | 13 (7.3%) | ||||
| 7 | 5 (2.5%) | 0 (0%) | 5 (2.8%) | ||||
| 8 | 3 (1.5%) | 2 (10%) | 1 (0.6%) | ||||
| 9 | 1 (0.5%) | 1 (5%) | 0 (0%) | ||||
| Presence of any warning signs | 198 | 190 (95.5%) | 20 | 20 (100%) | 178 | 170 (95.0%) | 1.00a |
| Severe dengue by type | |||||||
| Decompensated shock | 58 (29.1%) | 10 (50%) | 48 (26.8%) | ||||
| Compensated shock | 69 (34.7%) | 4 (20%) | 65 (36.3%) | ||||
| Respiratory compromise | 42 (21.1%) | 2 (10%) | 40 (22.3%) | ||||
| Severe bleeding | 24 (12.1%) | 10 (50%) | 14 (7.8%) | ||||
| Severe hepatitis | 40 (20.1%) | 8 (40%) | 32 (17.9%) | ||||
| AKI | 35 (17.6%) | 8 (40%) | 27 (15.1%) | ||||
| Encephalitis | 6 (3.0%) | 2 (10%) | 4 (2.2%) | ||||
| Other | 5 (2.5%) | 1 (5%) | 4 (2.2%) | ||||
| Number of types of severe dengue | NSb | ||||||
| 1 | 139 (69.8%) | 12 (60%) | 127 (70.9%) | ||||
| 2 | 53 (26.6%) | 4 (20%) | 49 (27.4%) | ||||
| 3 | 5 (2.5%) | 3 (15%) | 2 (1.1%) | ||||
| 4 | 2 (1.0%) | 1 (5%) | 1 (0.6%) | ||||
| Blood products given | 198 | 57 (28.8%) | 20 | 18 (90%) | 178 | 39 (21.9%) | < 0.0001 |
| SBP, mmHg | 198 | 103 (90–120) | 20 | 98 (87–133) | 178 | 103 (90–118) | 0.88 |
| DBP, mmHg | 198 | 63 (53–74) | 20 | 60.5 (48–84) | 178 | 63 (54–74) | 0.92 |
| MAP, mmHg | 198 | 77 (65–89) | 20 | 74.3 (61–102) | 178 | 77.3 (66–88) | 0.96 |
| PR, beats per minute | 197 | 98 (86–110) | 20 | 110 (102–120) | 177 | 96 (86–109) | 0.01 |
| Shock Index, bpm/mmHg | 197 | 1.2 (1.0–1.5) | 20 | 1.3 (1.0–1.9) | 177 | 1.2 (1.0–1.4) | 0.25 |
| RR, breaths/min | 182 | 20 (18–24) | 20 | 22 (19–30) | 162 | 20(18–23) | 0.07 |
| WBC, ×103/μL | 198 | 4.2 (2.9–5.7) | 20 | 5.3 (2.7–8.4) | 178 | 4.1 (2.9–5.6) | 0.15 |
| Hb, g/dL | 198 | 14.2(12.3–16.2) | 20 | 13.9 (11.7–17.1) | 178 | 14.2 (12.3–16.1) | 0.97 |
| Hct, % | 198 | 42 (37–47.0) | 20 | 42.5 (31.0–49.5) | 178 | 42 (37.0–47.0) | 0.91 |
| Platelet, × 103/μL | 197 | 43 (16–97) | 20 | 26 (8–41) | 177 | 53 (18–105) | 0.005 |
| Serum creatinine, μmol/L | 195 | 79 (63–101) | 20 | 110 (67–333) | 175 | 75 (63–97) | 0.01 |
| AST, U/L | 184 | 165 (66–600) | 19 | 1175 (123–1920) | 165 | 152 (63–456) | 0.01 |
| ALT, U/L | 192 | 104 (34–257) | 20 | 365 (62–755) | 172 | 95 (31–211) | 0.01 |
| Troponin T, ng/mL | 17 | 0.02 (0.009–0.3) | 6 | 0.4 (0.05–1.9) | 11 | 0.009 (0.007–0.03) | 0.10 |
| Serum bicarbonate, mmol/L | 192 | 21.1 (18.5–23.1) | 20 | 16.2 (11.2–18.8) | 172 | 21.5 (19.4–23.2) | < 0.0001 |
| Serum lactate, mmol/L | 149 | 1.6 (1.1–2.3) | 19 | 3.2 (2.1–6.5) | 130 | 1.5 (1.1–2.1) | < 0.0001 |
| Nadir WBC, × 103/μL | 198 | 2.7 (1.94–3.8) | 20 | 2.6 (2.1–4.1) | 178 | 2.7 (1.9–3.7) | 0.47 |
| Highest Hct, % | 198 | 45.1 (40.9–49.0) | 20 | 46.9 (41.0–50.2) | 178 | 45.0 (40.9–49.0) | 0.38 |
| Nadir Platelet, × 103/μL | 198 | 18 (7–44) | 20 | 7 (2–21) | 178 | 19 (8–45) | 0.005 |
| Highest serum creatinine, μmol/L | 198 | 87 (69–112) | 20 | 249 (175–378) | 178 | 83 (68–102) | < 0.0001 |
| Highest AST, U/L | 193 | 262 (100–1024) | 20 | 4763 (658–21,547) | 173 | 244 (98–589) | < 0.0001 |
| Highest ALT, U/L | 197 | 147 (58–450) | 20 | 1243 (243–3780) | 177 | 117 (55–303) | < 0.0001 |
| Highest Troponin T, ng/mL | 22 | 0.01 (0.005–0.3) | 5 | 0.7 (0.1–1.9) | 17 | 0.01 (0.005–0.03) | 0.07 |
| Lowest Serum bicarbonate, mmol/L | 195 | 19.5 (16.9–21.4) | 20 | 8.5 (6.7–13.1) | 175 | 19.9 (17.9–21.5) | < 0.0001 |
| Highest Serum lactate, mmol/L | 189 | 1.9 (1.3–2.8) | 20 | 16.0 (6.7–18.5) | 169 | 1.8 (1.2–2.3) | < 0.0001 |
| Total fluids given, mL | 193 | 6034 (3470–8707) | 20 | 9808 (7184–16,692) | 173 | 5610 (3307–8259) | 0.0004 |
n count of non-missing observations; aFisher’s exact test; bPost-hoc multiple comparisons tests using Scheffe’s method; IQR interquartile range, BMI body mass index, COPD chronic obstructive airway disease, BA bronchial asthma, DM diabetes mellitus, IHD ischemic heart disease, NS1 non-structural protein 1 antigen, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pressure, PR pulse rate, RR respiratory rate, AST aspartate transaminase, ALT alanine transaminase, WBC white blood cell count, Hct hematocrit, AKI acute kidney injury, NS not significant
Timing of clinical events in 199 patients hospitalised with severe dengue in 2014
| All ( | Died ( | Survived ( | |||||
|---|---|---|---|---|---|---|---|
|
| n (%) or median (IQR) |
| n (%) or median (IQR) |
| n (%) or median (IQR) | ||
| 199 | 4.00 (2.81–5.00) | 20 | 3.51 (2.58–4.38) | 179 | 4.03 (2.93–5.00) | 0.29 | |
| 198 | 4.63 (3.56–5.67) | 20 | 4.07 (3.22–5.81) | 178 | 4.65 (3.66–5.67) | 0.39 | |
| 194 | 4.96 (3.92–6.04) | 18 | 4.08 (3.00–5.13) | 176 | 5.02 (4.03–6.13) | 0.05 | |
| 199 | 8.75 (7.16–11.0) | 20 | 6.81 (4.91–12.82) | 179 | 8.80 (7.46–10.67) | 0.08 | |
| Phase at admission, febrile | 194 | 153 (78.8) | 18 | 10 (55.6) | 176 | 143 (81.3) | 0.03a |
| Phase at severe dengue diagnosis, febrile | 193 | 114 (59.1) | 18 | 6 (33.3) | 175 | 108 (61.7) | 0.02 |
| Severe dengue upon presentation | 198 | 73 (36.9) | 20 | 8 (40.0) | 178 | 65 (36.5) | 0.76 |
| 199 | 4.63 (3.75–5.71) | 20 | 3.74 (2.93–5.34) | 179 | 4.71 (3.88–5.73) | 0.07 | |
| 199 | 5.50 (4.64–6.50) | 20 | 4.79 (3.40–6.96) | 179 | 5.54 (4.79–6.50) | 0.11 | |
| 197 | 5.00 (3.92–6.04) | 20 | 5.36 (3.56–8.94) | 177 | 4.92 (3.96–5.92) | 0.15 | |
| 190 | 5.38 (4.13–6.60) | 20 | 5.44 (3.93–9.70) | 170 | 5.35 (4.13–6.50) | 0.32 | |
| 198 | 5.56 (4.42–6.75) | 20 | 5.41 (4.05–7.02) | 178 | 5.58 (4.42–6.75) | 0.88 | |
| 194 | 5.35 (4.29–6.54) | 20 | 5.26 (4.18–7.39) | 174 | 5.35 (4.38–6.50) | 0.81 | |
| 199 | 4.67 (3.67–5.79) | 20 | 4.81 (4.00–8.38) | 179 | 4.67 (3.58–5.71) | 0.10 | |
n count of non-missing observations; aFisher’s exact test; IQR interquartile range, WBC white blood cell count, AST aspartate transaminase, ALT alanine transaminase; 1–11 These are days from onset of fever
Multivariate analysis of potential factors that predict mortality at the time of diagnosis of severe dengue
| Parameters | Adjusted OR | 95% CI |
|
|---|---|---|---|
| Lethargy | 3.84 | (1.23–12.03) | 0.0208 |
| Bleed | 8.88 | (2.91–27.15) | 0.0001 |
| Multiple co-morbidities | 1.28 | (0.32–5.15) | 0.7258 |
| Pulse rate | 1.04 | (1.01–1.07) | 0.0058 |
| Serum bicarbonate | 0.79 | (0.70–0.89) | < 0.0001 |
| Serum lactate | 1.27 | (1.09–1.47) | 0.0019 |
| Plt | 0.981 | (0.97–1.00) | 0.0231 |
| ALT | 1.001 | (1.00–1.002) | 0.0046 |
| AST | 1.001 | (1.00–1.001) | 0.0152 |
| Serum creatinine | 1.008 | (1.00–1.01) | 0.0044 |
OR odds ratio, CI confidence interval
Area under curve of receiver operating curve (AUROC) of models for predicting mortality among cases of severe dengue
| Model | AUROC (95% CI) |
|---|---|
| Serum bicarbonate - ALT | 83.5 (72.4–94.6) |
| Serum bicarbonate - Pulse rate | 83.4 (73.5–93.4) |
| Serum bicarbonate - Serum creatinine | 83.1 (72.0–94.3) |
| Serum bicarbonate - Bleed | 82.9 (70.5–95.2) |
| Serum lactate - ALT | 80.8 (67.2–94.4) |
| Serum lactate - Pulse rate | 78.7 (65.7–91.8) |
| Serum lactate - Serum creatinine | 77.7 (63.9–91.5) |
| Serum lactate - Bleed | 81.1 (68.2–94.0) |
AUROC area under curve; CI confidence interval
Fig. 1Cross-validated and uncross-validated (basic) ROC curves of the serum bicarbonate - ALT model